Acalabrutinib
Calquence · BTKi · BTK
Second-generation covalent BTK inhibitor. More selective than ibrutinib with fewer off-target kinase effects.
Relapsed/refractory MCL after at least one prior therapy
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Pharmacological research · Apr 2026
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.
Blood advances · Mar 2026
A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.
Oncology and therapy · Mar 2026
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.
Blood advances · Feb 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 2026
[Acalabrutinib plus bendamustine and rituximab for older patients with untreated mantle cell lymphoma].
Bulletin du cancer · Feb 2026
Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors.
Cancers · Jan 2026
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.
Biomolecules · Jan 2026
Emerging first-line treatment approaches for mantle cell lymphoma.
Leukemia & lymphoma · Jan 2026
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
European journal of haematology · Dec 2025
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.
Leukemia & lymphoma · Dec 2025
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma.
International journal of clinical oncology · Nov 2025
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.
Future oncology (London, England) · Oct 2025
Successful Treatment of Paraneoplastic Mesangioproliferative Glomerulonephritis in Mantle Cell Lymphoma Using Acalabrutinib and Rituximab.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · Oct 2025
Acalabrutinib alleviates metabolic dysfunction-associated steatotic liver disease by regulating bile acid metabolism.
The international journal of biochemistry & cell biology · Aug 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 2025
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.
Pharmacological research · Jul 2025
A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo.
Cancers · Jun 2025
A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.
British journal of haematology · May 2025
From development to clinical success: the journey of established and next-generation BTK inhibitors.
Investigational new drugs · Apr 2025